Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential
Cathleen Juhl(Leipzig University), Donald Bierer(Bayer (Germany)), Frank Wunder(Drug Discovery Laboratory (Norway)), Erik Haaf(Bayer (Germany)), Nils Burkhardt(Bayer (Germany)), Bernd Riedl(Bayer (Germany)), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), Ria Schönauer(Charité - Universitätsmedizin Berlin), Sylvia Els‐Heindl(Leipzig University), Gorden Redlich(Bayer (Germany))
Cited by 34
Related Papers
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin
|Endocrinology|2006|432
Herbal drugs and phytopharmaceuticals
|Pharmaceutica Acta Helvetiae|1995|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
|European Journal of Pharmacology|1994|374